TABLE 3.
Reduction in inflammatory lesions with various treatment times*
| ENDPOINT | DOXYCYCLINE | MINOCYCLINE | SARECYCLINE | AZITHROMYCIN | TMP-SMX |
|---|---|---|---|---|---|
| 3 weeks | NA | 65%59 | NA | 55%59 | NA |
| 4 weeks | 25–46% 17,21,60 | 32%36 | NA | 23%60 | NA |
| 5 weeks | NA | NA | NA | NA | 62%+6 |
| 6 weeks | NA | 51% | NA | NA | NA |
| 8 weeks | 39%60 | 41%–69%17,21,36 | NA | 36%60 | NA |
| 10 weeks | NA | NA | NA | NA | 48% +56 |
| 12 weeks | 48%–75%17,60 | 27%–91%13,17,36 | 50%–52%43,44 | 55%60 | NA |
| 16 weeks | 23% to 51%17,44,60 | NA | NA | NA | NA |
| 18 weeks | NA | 22%13,17 | NA | NA | NA |
| 20 weeks | NA | 52%13,17 | NA | NA | NA |
| 24 weeks | 50%17,21 | 74%13,17,21 | NA | NA | NA |
NA: not available
+TMP-SMX study did not evaluate absolute number of inflammatory lesions but rather a grade based on number and severity of lesions56
*Doses may differ across studies